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Outline
• Global prevalence, risk, and mortality from smoking
• Gender/Sex specific diseases associated with tobacco use
• Gender/Sex specific reasons for smoking
• Gender/Sex specific factors in treating tobacco use

Global prevalence, risk, and mortality from
smoking

“Cigarettes are like women. The best ones are
thin and rich.”
American Tobacco Company advertising slogan, US, circa 1970

“I’m no cowboy and I don’t ride horseback, but I like to
think I have the freedom the Marlboro man exemplifies.
He’s the man who doesn’t punch a clock. He’s not
computerized. He’s a free spirit.”
George Weissman, Former President and CEO, Philip Morris USA, 1978

800 million adult men worldwide smoke cigarettes. Almost 20% of the world’s adult male
smokers live in high-income countries, while over 80% are in low- and middleincome countries.

Nearly 200 million adult women smoke worldwide

Global Mortality Estimates
• In 2011, tobacco use killed almost 6 million people (80%
of deaths occurring in low-and middle-income countries)
• Tobacco use is responsible for up to 15% of all deaths
among men and 7% of all deaths among women globally
(smoking also causes almost 80% of male and nearly
50% of female lung cancer deaths)

• Approximately 600, 000 nonsmokers died in 2011 from
involuntary exposure to secondhand smoke.
“Tobacco caused 100 million deaths during the twentieth century, and if
current trends continue, approximately 1 billion people will die during
the twenty–first century because of tobacco use”
Tobacco Atlas 4th edition (www.tobaccoatlas.org)

Gender/Sex specific diseases associated with tobacco use

Cancers1
Bronchus
Esophagus
Cervix uteri
Stomach2
Leukemia2
Kidney,
other urinary

Lung,
Lip, Oral cavity/pharynx
Larynx, trachea
Urinary bladder
Colon2
Pancreas
Liver2

Cardiovascular disease1
Ischemic heart disease
Cerebrovascular disease
Rheumatic heart disease
Atherosclerosis
Hypertension
Aortic aneurysm
Pulmonary heart disease
Other arterial disease

#1 Lung cancer
#2 Ischemic heart disease
#3 Chronic airways
obstruction1
Respiratory disease1
Chronic airways obstruction
Asthma
Bronchitis/emphysema
Pneumonia/influenza
Respiratory tuberculosis
Paediatric disease1
Low birth weight
Respiratory conditions-newborn
Respiratory distress syndrome
Sudden Infant Death Syndrome
Reproductive Problems2
Reduced fertility
Spontaneous Abortion
Placental abruption

1. Makomaski Illing EM, Kaiserman, MJ. Can J Public Health 2004;95:38-44.
2. Ghadirian, P (for Health Canada). Sleeping with a Killer: The Effects of Smoking on Human Health. Health Canada. Sept. 2002.

Lung cancer risk may be higher in women,
both among smokers (shown here) and
nonsmokers
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USDHHS (1989) Surgeon General’s Report: Reducing the health consequences of smoking.
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Relative risk of myocardial infarction for current
smokers compared with never smokers, by sex
Prescott et al. (1998) Smoking and risk of myocardial infarction in women
and men: longitudinal population study. Brit Med J 316: 1043-1047

Disease risk I

Meta-analyses examining the risk for a variety of diseases
associated with smoking in English language studies:
For smokers of <20 cigarettes per day, the rate ratio point
estimate was1.42 for males and 1.77 for females.
For smokers of ≥20 cigarettes per day, the point estimate was
1.95 for males and 2.75 for females.
The increase in risk from low to high levels of smoking was
greater for females than for males.

Mucha et al. (2006). Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking.

Disease risk II
Meta-analyses examining the risk for cardiovascular diseases
associated with smoking in Asian and Australian/New Zealand (ANZ)
studies
Lower mean daily cigarette consumption among females (10 in Asia; 15 in
ANZ) compared with males (16 and 20, respectively)
For both CHD and stroke, hazard ratios comparing smokers of ≥20
cigarettes per day with non-smokers were higher for women than men.

Asia Pacific Cohort Studies Collaboration (2005). Smoking, quitting, and the risk of cardiovascular disease among women and men in
the Asia-Pacific region.

Gender/Sex specific reasons for smoking

Sex differences in factors which influence tissue response
to nicotine (pharmacodynamics)

•
•
•

Female mice less sensitive to the acute effects of nicotine
Progesterone and 17b-estradiol were found to block nicotine’s
antinociception in mice. Testosterone failed to do so.
Progesterone and 17b-estradiol blocked nicotine activation of a4b2
neuronal acetylcholine nicotinic receptors expressed in oocytes.

2. Sex differences which lead to systemically higher or lower
plasma nicotine levels (pharmacokinetics)

• No significant difference was found in the number of cigarettes per day
or CO levels between the sexes.
• Females had significantly lower nicotine levels than males (16.9 ± 0.6 vs.
21.1 ± 0.07, p < 0.01)
• Female heavy smokers demonstrated higher -log nicotine/CO values (a
representation of cost of smoking) compared with male heavy smokers
(0.1 ± 0.02 vs. 0.02 ± 0.01 mg/L ppm, p < 0.05).

Sex/Gender Differences in non-pharmacological stimuli
and drug (i.e., conditioned responses)
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• Removal of lit cigarette cue decreases smoking reinforcement (VR)
more in women than in men.
Based on Perkins KA et al. (1994) Pharmacology, Biochemistry & Behavior 47: 107-112

Based on Perkins KA et al. (1994) Pharmacology, Biochemistry & Behavior 47:107-112
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Biopychosocial (i.e., gender) factors which differentiate
men and women
Common reasons boys start
smoking:

Common reasons young women
start smoking

•peer pressure
•misconceptions that smoking is cool or
enhances popularity
•easy access to tobacco products
•cigarette pricing
•tobacco marketing.

•Association with others (parents and
friends) who smoke
•Concern with weight, body image, or
social acceptance
•Interest in rebelling or stating
individuality
•Reaction to positive image of
smoking in magazines, movies, and
youth culture
•Influence from cigarette marketing
campaigns targeting women

Gender/Sex specific factors in treating tobacco use

Nicotine Replacement Therapy Outcome
Two meta-analyses examining nicotine replacement therapy
(NRT) for smoking cessation  Women less successful than
men.
1. Cepeda-Benito et al. (2004)  21 RCTs with different NRT
products:


NRT more effective than placebo at each follow-up for men.



Benefits for women clearly evident only at 3- and 6-month.
 at 6 month only in combination with high-intensity counselling.



At 12 month, NRT was not superior to placebo for women,
regardless of counselling intensity.



Effect sizes decreased over time for both men and women,
but the decline was statistically significant only for women.

Cepeda-Benito et al. (2004). Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences
between men and women.

Nicotine Patch Therapy Outcome

2. Perkins & Scott (2008)  14 RCTs with nicotine patch:
 6-months abstinence rates for NRT versus placebo were
20.1% versus 10.8% for men, and 14.7% versus 10.1% for
women.
 Increase in quitting due to nicotine versus placebo was only
about half as large in women as in men (ORs: 2.2 versus
1.6).
 NNTs: 10 for men and 19 for women  almost twofold
increase in the estimated number needed to treat for
women relative to men to get one additional long-term
abstinent ex-smoker.

Perkins & Scott (2008). Sex differences in long-term smoking cessation rates due to nicotine patch.

Bupropion Outcome

Meta-analyses examining bupropion for smoking cessation
 12 RCT’s with Bupropion 300mg SR versus Placebo:
 Both women and men benefited from bupropion as
compared to placebo.
 Women and men benefited equally from bupropion
treatment, no sex differences were found in its
effectiveness.
 However, women were less likely than men to quit smoking,
regardless of treatment type.

Scharf & Shiffman (2004). Are there gender differences in smoking cessation, with and without bupropion? Pooled- and metaanalyses of clinical trials of Bupropion SR

Women-specific interventions
Treatment models

Treatment components

Weight concerns/weight gain are
greater in women than in men

• Behavioural strategies to prevent weight gain;
• Medications to prevent weight gain;
• Cognitive strategies to reduce weight and body
image concerns.

Negative affect/depression present Strategies to reduce /cope with negative affect:
special challenges for women
• behavioural (e.g., exercise);
• coping skills /stress management training
• medication (e.g., bupropion)
The psychological aspects of
smoking and the cues associated
with smoking present special
challenges for women

• Cognitive-behavioural strategies to manage
situations which trigger craving.

Nicotine withdrawal is higher
during the luteal than during the
follicular phase of the menstrual
cycle

Scheduling the quit date according to the menstrual
cycle

• Medication to reduce the rewarding effects of
nicotine: Naltrexone

Torchalla, Okoli, Bottorff, Qu, Poole, & Greaves (2011). Smoking cessation programs targeted to women: A systematic review.

Women-specific interventions
Treatment models

Treatment components

• Certain sociocultural populations
are hard to reach.

• Peer lay counselors who share commonalities
with the target group (e.g. language, culture,
attitudes, beliefs).

• Treatment needs to account for
their characteristics.
• Counselors must be able to
communicate with them and act
as role models.

Women receiving health services
may be specifically receptive for
proactive smoking cessation
intervention.

• Socioculturally adapted materials and
components

• Brief motivational interventions (counseling
plus telephone calls / letters).
• Additionally: tailored/gendered booklets,
video/poster exposure.
• Or: mailings / telephone calls only (no face-toface contact).

Torchalla, Okoli, Bottorff, Qu, Poole, & Greaves (2011). Smoking cessation programs targeted to women: A systematic review.

Outcomes
•

Programs addressing exercise, weight gain/-concerns:
Promising results, at least in the short term.

•

Mood management / stress management : no significant main
effect, especially when compared to contact-matched programs.
Counselling x medication effects possible.

•

Matching the quit date to the menstrual cycle: no consistent
effects.

•

Peer counselling: preliminary promising results.

•

Interventions without face-to-face contact: no medium- and
long-term effects reported.

•

Brief interventions in public health clinics: significantly higher
medium-term abstinence rates compared to usual care

Torchalla, Okoli, Bottorff, Qu, Poole, & Greaves (2011). Smoking cessation programs targeted to women: A systematic review.

Conclusions
 Women-specific tobacco programs help women stop smoking.
 The choice of treatment for an individual smoker can be guided by
client’s preferences.
 Health care providers should be encouraged to address women’s
smoking proactively and in any setting.
 Future research:
 Identify those elements that are essential for designing womenspecific smoking cessation programs.
 Develop more creative and multifaceted women-specific
programs, addressing the full range mechanisms relevant for
women’s smoking behaviour.

Torchalla, Okoli, Bottorff, Qu, Poole, & Greaves (2011). Smoking cessation programs targeted to women: A systematic review.
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Description of study
Author (Year)

Design

Sample
size

Components

% Quit at
EOT

Rose & Hamilton, (1978)

RCT

1445

Quit advice from Physician

31.8%*

Li, et al., (1984)

RCT

576

Behavioural Counseling

8.4%*

Burling et al., (1991)

RCT

39

Relapse Prevention + Nicotine fading +
Contingency management

26.3%*

Pallonen et al., (1994)

RCT

265

Self-help manual

25%*

Jenkins et al., (1997)

Pre-Post

2714

Media led anti-tobacco interventions

7.2%

Kalman et al., (2001)

RCT

36

Individuals counseling + Nicotine Patch +
substance use counselling

16.6%

Stanton et al., (2004)

RCT

561

Video + nicotine patch + support material

16.5%*

Harding, Bensley, & Corigan,
(2005)

Cohort

69

Behavioural counselling + peer support +
Nicotine replacement

64%

Loke & Lam (2005)

RCT

758

Advice on encouraging husbands to quit

6.1%

Richmond et al., (2006)

Cohort

30

Behavioural counselling + Nicotine
replacement + Bupropion

37%

Gershon Grand et al., (2007)

Cohort

231

Behavioural counselling + Nicotine
replacement + Bupropion

36.4%
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Discussion
• Associations with Sex & Gender:
– No study specifically designed the intervention with sex or
gender in consideration.
– No study examined sex or gender differences in outcomes
among men
– Three studies were ‘men-centred’ – two examined expectant
fathers, and one study addressed ‘gay’ men.

• Associations with smoking cessation :
– The most effective studies utilized combinations of behavioural
counselling, nicotine replacement therapy and peer support.
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Future directions
• Need for studies examining sex and gender differences
in smoking cessation outcomes.
• Development of ‘women- centred’ and ‘men-centred’
interventions, tailored appropriately to the targetted male
and female populations.
• Further exploration of gendered factors associated with
smoking cessation interventions and outcomes.

